Clinical Trial Update: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, safety and tolerability of TMC435 (simeprevir) in genotype 1 hepatitis C patients who relapsed after prior therapy; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Olysio (simeprevir) (simeprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-04-23